AAO 2019

    In this interview from AAO 2019, Dr. Carol Shields discusses a new light-activated nanoparticle therapy (AU-011) for ocular melanoma. The particle, which is attached to a chromophore, binds to melanoma cells and is activated by a 689-nanometer light. Early-stage trials look promising, she explains, with preliminary results demonstrating minimal vision loss, suggesting this treatment may be a good alternative to plaque radiotherapy. Although the current treatment is injected into the vitreous, she hopes to test if the particle will be more effective if it is delivered directly to the choroid.

    Relevant Financial Disclosures: Dr. Carol Shields is a consultant for Aura Biosciences.